Irbepress (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors, preventing angiotensin II from causing blood vessels to narrow and from stimulating aldosterone release. This results in vasodilation, reduced sodium retention, lower blood pressure, and protective effects on the kidneys.

The appropriate dose of Irbepress is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of irbesartan in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Irbepress, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Irbepress (irbesartan) belongs to the ARB class, which is often preferred for patients who cannot tolerate ACE inhibitors due to cough. Compared with ACE inhibitors, ARBs have a lower incidence of dry cough and similar efficacy in lowering blood pressure and protecting renal function.

Irbepress tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Irbepress is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse reactions, although rare, include angioedema (swelling of the face, lips, tongue, or airway), acute renal failure, and severe hypotension. Patients should seek immediate medical attention if they experience any signs of these conditions.

Irbepress should be avoided in individuals with known hypersensitivity to irbesartan or other ARBs, in patients with severe liver impairment, and in those taking aliskiren if they have diabetes. It should also be used with caution in patients with compromised renal function or electrolyte disturbances.